Get the Stockscreener App
4.75
8.20%
0.36
After Hours:
4.75
Alumis Inc stock is traded at $4.75, with a volume of 865.09K.
It is up +8.20% in the last 24 hours and up +36.10% over the past month.
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.
See More
Previous Close:
$4.39
Open:
$4.45
24h Volume:
865.09K
Relative Volume:
0.97
Market Cap:
$456.02M
Revenue:
-
Net Income/Loss:
$-238.77M
P/E Ratio:
-0.1772
EPS:
-26.808
Net Cash Flow:
$-216.62M
1W Performance:
+10.47%
1M Performance:
+36.10%
6M Performance:
-8.83%
1Y Performance:
-63.09%
1-Day Range:
$4.4422
$4.77
1-Week Range:
$4.0911
$4.77
52-Week Range:
$2.7601
$13.11
Alumis Inc Stock (ALMS) Company Profile
Name
Alumis Inc
Sector
Industry
Phone
650-231-6625
Address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
4.75 | 453.00M | 0 | -238.77M | -216.62M | -26.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Initiated | Wells Fargo | Overweight |
| Jun-10-25 | Resumed | Guggenheim | Buy |
| Jan-30-25 | Initiated | Oppenheimer | Outperform |
| Oct-31-24 | Initiated | Robert W. Baird | Outperform |
| Oct-17-24 | Initiated | H.C. Wainwright | Buy |
| Jul-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-23-24 | Initiated | Guggenheim | Buy |
| Jul-23-24 | Initiated | Leerink Partners | Outperform |
| Jul-23-24 | Initiated | Morgan Stanley | Overweight |
View All
Alumis Inc Stock (ALMS) Latest News
Is Alumis Inc. stock a good hedge against inflationWeekly Investment Summary & Fast Exit and Entry Trade Guides - Newser
Is Alumis Inc. a stock for growth or value investorsJuly 2025 Momentum & Detailed Earnings Play Strategies - classian.co.kr
What high frequency data says about Alumis Inc.Entry Point & Risk Managed Investment Signals - Newser
Can machine learning forecast Alumis Inc. recoveryWeekly Investment Recap & Stock Timing and Entry Methods - Newser
Alumis Inc. Builds Base for Possible ReboundWeekly Risk Summary & Consistent Profit Trading Strategies - metal.it
Alumis Inc.: A Biopharma Bargain Amid Clinical Catalysts and Analyst Optimism - AInvest
Alumis Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates - simplywall.st
Alumis Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - 富途牛牛
Predicting Alumis Inc. trend using moving averagesOptions Play & Community Driven Trade Alerts - Newser
How Alumis Inc. stock performs during market volatilityPortfolio Value Report & Daily Stock Trend Reports - thegnnews.com
Relative strength of Alumis Inc. in sector analysisJuly 2025 Opening Moves & Entry and Exit Point Strategies - Newser
Reversal indicators forming on Alumis Inc. stockWeekly Risk Report & AI Forecasted Entry and Exit Points - Newser
Alumis Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Alumis Inc. shares fall 1.36% intraday after reporting Q2 2025 financial results and merger with Acelyrin. - AInvest
Cantor Fitzgerald reiterates Overweight rating on Alumis stock amid post-merger decline - Investing.com Australia
Alumis Inc.: Strong Buy Rating Backed by Promising Drug Candidate and Strategic Positioning - TipRanks
Alumis Misses Q2 Revenue as Costs Jump - AOL.com
Alumis Q2 Revenue Down 5% YoY, Cash to Fund Ops into 2027 - AInvest
Alumis reports Q2 revenue $2.67M, consensus $2.43M - TipRanks
Alumis Hits Major Milestone in Psoriasis Drug Development, Strengthens Pipeline with $486M War Chest - Stock Titan
Alumis Inc. (NASDAQ:ALMS) Given Average Recommendation of “Buy” by Brokerages - Defense World
What momentum shifts mean for Alumis Inc.Free Entry Plan for Oversold Reversal Stocks - Newser
Is Alumis Inc. reversing from oversold territoryPredictive Short-Term Market Reversal Alerts - Newser
While institutions invested in Alumis Inc. (NASDAQ:ALMS) benefited from last week's 4.1% gain, individual investors stood to gain the most - uk.finance.yahoo.com
Why Alumis Inc. stock attracts strong analyst attentionMassive Upside Stock List - thegnnews.com
Alumis Inc.'s (NASDAQ:ALMS) market cap touched US$444m last week, benefiting both retail investors who own 38% as well as institutions - simplywall.st
Alumis Inc. (NASDAQ:ALMS) Stock Position Boosted by Bank of New York Mellon Corp - Defense World
Alumis Inc. Concludes 2025 Annual Stockholders Meeting - The Globe and Mail
How strong is Alumis Inc. company’s balance sheetMassive stock growth - Jammu Links News
What is the dividend policy of Alumis Inc. stockGet alerts on high-potential stock breakouts - Jammu Links News
Should I hold or sell Alumis Inc. stock in 2025Build a portfolio that outperforms consistently - Jammu Links News
When is Alumis Inc. stock expected to show significant growthBuild a winning portfolio with smart picks - Jammu Links News
What drives Alumis Inc. stock priceInvest confidently with real-time data analysis - Jammu Links News
How volatile is Alumis Inc. stock compared to the marketInvest in stocks with strong fundamentals - Jammu Links News
What are analysts’ price targets for Alumis Inc. in the next 12 monthsCapitalize on trading strategies that deliver - Jammu Links News
What institutional investors are buying Alumis Inc. stockTurn volatility into profit opportunities - Jammu Links News
How many analysts rate Alumis Inc. as a “Buy”Build wealth steadily with expert advice - Jammu Links News
Confident Outlook on Acelyrin-Alumis Merger Amid Shareholder Opposition - TipRanks
How does Alumis Inc. compare to its industry peersDaily Trading Outlook With Proven Results - Jammu Links News
Is Alumis Inc. a growth stock or a value stockStock Strategy Tracker For Every Investor - Jammu Links News
Alumis Inc. shares rise 5.19% intraday after Brag House Holdings, Inc. announced successful conclusion of 'Brag Gators Gauntlet: Preseason Edition. - AInvest
What makes Alumis Inc. stock price move sharplyAI Driven Stock Trend Forecast Shows Momentum Shift - metal.it
Alumis (ALMS) Merges with ACELYRIN - Insider Monkey
Alumis Inc. Completes Merger with ACELYRIN, Boosts Balance Sheet and Advances Pipeline - AInvest
What is the risk reward ratio of investing in Alumis Inc. stockHarness the power of proven investment plans - jammulinksnews.com
Alumis Inc.: Promising Pipeline and Strategic Advancements Justify Buy Rating - TipRanks
How does Alumis Inc. generate profit in a changing economyPre Market Target Finder For 2025 - Jammu Links News
What markets is Alumis Inc. expanding into Is ELPW stock a good long term investment optionMaximize returns with smart investment plans - Jammu Links News
Alumis Inc Stock (ALMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):